The approval of Biogen Idec’s MS therapy Tecfidera follows months of breathless Wall Street hype, and it looks like doctors are psyched for the drug, too. In a MedLIVE PULSE survey conducted by WorldOne...
Drug pipelines far from full, report finds
By
McKnight's Staff
Oct 01, 2012
With new and novel medicines launched the last couple of years for diseases such as cancer, hepatitis C virus and multiple sclerosis, one would think that pharmaceutical pipelines are gradually improving....
Relias Learning continues to purchase online learning foes
By
Elizabeth Newman
Dec 04, 2015
Relias Learning has completed the acquisition of fellow professional education company RediLearning. The deal will allow 400 new senior care courses to be merged into the Relias library.
Omnicare extends PharMerica buy offer
By
John O'Connor
Jan 03, 2012
Pharmacy giant Omnicare announced that it was extending to Jan. 20 its offer to purchase all outstanding shares of rival PharMerica for $15 per share. The original offer had been scheduled to expire in...